Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaRetinoic acid and arsenic for treating acute promyelocytic leukemiaHow animal models of leukaemias have already benefited patientsProgress in acute myeloid leukemiaTargeting of leukemia-initiating cells in acute promyelocytic leukemiaToxicology of chemically modified graphene-based materials for medical application.Synergistic effect of cell differential agent-II and arsenic trioxide on induction of cell cycle arrest and apoptosis in hepatoma cells.Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.Arsenic trioxide, a therapeutic agent for APL.Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation.Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaThe PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.Arsenic neurotoxicity--a review.The emergence of resistance to targeted cancer therapeutics.Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosisAntagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cellsThe effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells.Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic LeukemiaSelective Impairment of TH17-Differentiation and Protection against Autoimmune Arthritis after Overexpression of BCL2A1 in T LymphocytesAcute promyelocytic leukemia: a model of molecular target based therapy.Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinLong-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction.Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.BCL2A1: the underdog in the BCL2 family.Current treatment strategy of acute promyelocytic leukemia.Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia.The advancing uses of nano-graphene in drug delivery.Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
P2860
Q24605527-87F1645E-13DC-4A0E-9BA2-D25E4B86542CQ24809165-9B96267C-B660-405C-91B8-25108492F951Q26997702-479F4558-0211-40CE-ADC3-A9E73493D5BEQ27024006-D585075F-F34C-46FA-9473-5E81FD214D05Q28083807-23D4C95E-9D31-4462-81AD-CF80DAF6961BQ30427860-4DFC0E94-08D9-4E4B-BB04-1741823F1730Q33185585-BDA5710D-727F-43A0-95F7-77EA567D3529Q33291299-DBD0FD92-F727-463B-B64B-1A49D0A983BBQ34014502-95537002-1F6A-40E6-B8F9-A0D07ED2B115Q34046794-9DD3A28D-B6D9-40B2-B7D1-F6F55755CD74Q34435492-B5E087CE-704B-4DD8-B1DA-DCFCA739D50AQ34435506-E95C7644-4678-47D2-A56D-8694AA96C851Q34435558-06750351-B878-4188-8AB0-48C9CC9E417FQ34546653-063BBD47-0545-4DE2-A2D2-E4F9CC8B9D8DQ34548159-7644201C-F7EF-4855-B502-4B289018B0C8Q34575618-69C4D937-7D70-48A4-ABD9-003C4554F134Q34715170-CD94F1B9-1E58-4544-9D36-D3823AFB36D9Q34837015-A182CBB2-F5EE-4DE0-AB5A-42C127A3C547Q35070447-52DF9480-9EA5-47E9-96B3-8B5ED21CA8A3Q35677279-FBC99785-620E-41C7-B1F9-712C9DD535D2Q35888664-3AEBE145-D790-4C2E-97FD-178A644CCDD6Q35904994-0D0C68EB-EB7D-43EC-92FA-2ADA37FF3434Q36081545-3D576A92-8680-404A-8D15-E2D300647CCEQ36270144-67EC8237-2AED-40B0-9FB5-36C20ADF2D92Q36732473-CF7C6E45-D0C4-40EB-8A85-F780F67D17D3Q36938551-CE0ED165-FF74-435C-B8DB-37D924C27138Q37117735-C6B2B58F-DDCB-44A2-ABF4-BDB6A186A356Q37307720-399A2AC6-1D45-4B0A-B0D6-A41D31D94D33Q37397791-E001577F-6E81-41D2-9B09-5E99CBA1BC26Q37564637-CA837FE4-1503-46CC-B6EA-0A57EA59F8A0Q37890950-AB2FAB9D-4582-4915-BC72-DEA77A263243Q37929546-A6CF8413-08C0-4154-BF7D-7737C9F0C5D5Q37954995-61774129-E080-4D4D-91CC-2AADD93412C9Q37971327-1A1A4A93-4505-47D0-A728-8CE6C7259B07Q37999067-8A0BD1E0-CE00-465F-8F74-78F47B7BD0BDQ38240617-535C3088-A92D-4736-BF95-CC6DD530A4E0Q38281494-F945D1EF-25F7-4661-B216-1CAEE6D34B55Q38522309-DF6368E7-D3ED-4116-8CC6-8244A219B51CQ38730327-F254662B-6820-4C72-B0F6-8CFCE6B8D4F0Q38903506-21936478-0344-4DE8-A5D9-F8C8525E2A40
P2860
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Combined effect of all-trans r ...... ia cells in vitro and in vivo.
@en
Combined effect of all-trans r ...... ia cells in vitro and in vivo.
@nl
type
label
Combined effect of all-trans r ...... ia cells in vitro and in vivo.
@en
Combined effect of all-trans r ...... ia cells in vitro and in vivo.
@nl
prefLabel
Combined effect of all-trans r ...... ia cells in vitro and in vivo.
@en
Combined effect of all-trans r ...... ia cells in vitro and in vivo.
@nl
P2093
P356
P1433
P1476
Combined effect of all-trans r ...... ia cells in vitro and in vivo.
@en
P2093
P304
P356
10.1182/BLOOD.V97.1.264
P407
P577
2001-01-01T00:00:00Z